Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Sundell

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMC Medical Research Methodology|January 22, 2026
Discrete-time neural Markov modelsJesper Sundell, Ylva Wahlquist, Kristian Soltesz
Journal of Pharmacokinetics and Pharmacodynamics|October 21, 2023
Learning pharmacometric covariate model structures with symbolic regression networksYlva Wahlquist, Jesper Sundell, Kristian Soltesz
The Journal of Antimicrobial Chemotherapy|August 2, 2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIVJesper Sundell, Emile Bienvenu, Angela Äbelö, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2025
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass indexTeres Samuelsson, Elisabet Lönnermark, Jesper Sundell, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2022
Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV PatientsJesper Sundell, Emile Bienvenu, Sofia Birgersson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2019
Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIVJesper Sundell, Emile Bienvenu, Sofia Birgersson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2014
Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapiesTherese Ericsson, Jesper Sundell, Angelica Torkelsson, et al.
Clinical Pharmacology and Therapeutics|February 5, 2020
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing StrategyJesper Sundell, Emile Bienvenu, David Janzén, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 10, 2026
Learning Covariate Relations in Disease Progression Models Using Symbolic Neural NetworksJesper Sundell, Ylva Wahlquist, Maria C Kjellsson, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2021
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized DosingJesper Sundell, Marie Wijk, Emile Bienvenu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Medical Research Methodology|January 22, 2026
Discrete-time neural Markov modelsJesper Sundell, Ylva Wahlquist, Kristian Soltesz
Journal of Pharmacokinetics and Pharmacodynamics|October 21, 2023
Learning pharmacometric covariate model structures with symbolic regression networksYlva Wahlquist, Jesper Sundell, Kristian Soltesz
The Journal of Antimicrobial Chemotherapy|August 2, 2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIVJesper Sundell, Emile Bienvenu, Angela Äbelö, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2025
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass indexTeres Samuelsson, Elisabet Lönnermark, Jesper Sundell, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2022
Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV PatientsJesper Sundell, Emile Bienvenu, Sofia Birgersson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2019
Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIVJesper Sundell, Emile Bienvenu, Sofia Birgersson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2014
Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapiesTherese Ericsson, Jesper Sundell, Angelica Torkelsson, et al.
Clinical Pharmacology and Therapeutics|February 5, 2020
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing StrategyJesper Sundell, Emile Bienvenu, David Janzén, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 10, 2026
Learning Covariate Relations in Disease Progression Models Using Symbolic Neural NetworksJesper Sundell, Ylva Wahlquist, Maria C Kjellsson, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2021
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized DosingJesper Sundell, Marie Wijk, Emile Bienvenu, et al.
Pageof 2